Wednesday, October 18, 2023 9:46:36 PM
Missling said he is going to the fda first with Alz because they pay more. That’s a dumb azz move.
Just go where you can get approved. Enough slow walking this sht. You get the results and get all excited like a kid in a candy store. Start blabbering about AA everywhere and now radio silence.
No movement on our pipeline. Same catalysts for years. I pray that it’s because everyone is focused on approval. NDAs and partnerships. WTF else would they be doing.
That Parkinson’s imaging trial should have been a cake walk and long done.
You got all this promise. By the time any of this moves. The patents are gonna be expired. That’s why partnering is the right move. Get the damn drugs out there and start helping people. Partner and get these FN trials moving!!
What the fukin fuk Missling! It’s gonna be November soon and the holidays are upon us. I know things take time and results will come when they have them. But damn. Choose a good CRO. Hopefully they have one.
Apply everywhere like you said. Get sht moving! You had the same damn plan for years. Share price going to hell. Yea I’m pissed cuz I’m over leverages and have watched my profits evaporate. So FN what.
Enough dikcing around. Or we’ll see us in OTC again. You spend all this time and give us piecemeal half asz sht. Time for some, time for some, time for some action bich!!
Just go where you can get approved. Enough slow walking this sht. You get the results and get all excited like a kid in a candy store. Start blabbering about AA everywhere and now radio silence.
No movement on our pipeline. Same catalysts for years. I pray that it’s because everyone is focused on approval. NDAs and partnerships. WTF else would they be doing.
That Parkinson’s imaging trial should have been a cake walk and long done.
You got all this promise. By the time any of this moves. The patents are gonna be expired. That’s why partnering is the right move. Get the damn drugs out there and start helping people. Partner and get these FN trials moving!!
What the fukin fuk Missling! It’s gonna be November soon and the holidays are upon us. I know things take time and results will come when they have them. But damn. Choose a good CRO. Hopefully they have one.
Apply everywhere like you said. Get sht moving! You had the same damn plan for years. Share price going to hell. Yea I’m pissed cuz I’m over leverages and have watched my profits evaporate. So FN what.
Enough dikcing around. Or we’ll see us in OTC again. You spend all this time and give us piecemeal half asz sht. Time for some, time for some, time for some action bich!!
Recent AVXL News
- Anavex Life Sciences Highlights New Scientific Findings on Shared Biology Between Autism and Alzheimer’s Disease • GlobeNewswire Inc. • 04/14/2026 11:30:00 AM
- Anavex Life Sciences to Present at the 25th Annual Needham Virtual Healthcare Conference • GlobeNewswire Inc. • 04/07/2026 11:30:00 AM
- Anavex withdraws EU approval filing for Alzheimer’s therapy • IH Market News • 03/30/2026 12:39:26 PM
- Anavex Life Sciences Provides Comprehensive Regulatory Update • GlobeNewswire Inc. • 03/30/2026 11:30:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/25/2026 08:06:00 PM
- Anavex withdraws EU marketing application for Alzheimer’s therapy blarcamesine • IH Market News • 03/25/2026 02:06:58 PM
- Anavex Life Sciences Provides Update on Regulatory Review in the EU for Blarcamesine to Treat Early Alzheimer’s Disease • GlobeNewswire Inc. • 03/25/2026 11:30:00 AM
- Anavex Life Sciences Presents New Data from its AD-004 Phase IIb/III Trial at AD/PD 2026 Conference Demonstrating Consistent Correlation Between the Treatment Effect of Oral Blarcamesine and Preservation of Brain Volume in Early Alzheimer’s Disease • GlobeNewswire Inc. • 03/23/2026 11:30:00 AM
- New Scientific Findings Highlight Hypothesis of Autophagy Failure as a Precursor of Amyloid Beta and Tau Pathology in Alzheimer’s Disease • GlobeNewswire Inc. • 03/20/2026 11:30:00 AM
- Anavex Life Sciences Presents Significant Treatment Effects of Blarcamesine in New Advanced Alpha-Synuclein Model of Parkinson’s Disease at AD/PD 2026 Conference • GlobeNewswire Inc. • 03/17/2026 11:30:00 AM
- Anavex Life Sciences to Present at the Citizens Life Sciences Conference • GlobeNewswire Inc. • 03/03/2026 12:30:00 PM
- Anavex Life Sciences to Present at the 46th TD Cowen Annual Health Care Conference • GlobeNewswire Inc. • 02/25/2026 12:30:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/25/2026 11:07:01 AM
- Anavex Life Sciences Appoints Seasoned Healthcare Leader to Board of Directors • GlobeNewswire Inc. • 02/23/2026 12:30:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 02/09/2026 09:40:27 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/09/2026 12:31:17 PM
- Anavex Life Sciences Reports Fiscal 2026 First Quarter Financial Results and Provides Business Update • GlobeNewswire Inc. • 02/09/2026 12:30:00 PM
- Anavex Life Sciences to Announce Fiscal 2026 First Quarter Financial Results on Monday, February 9, 2026 • GlobeNewswire Inc. • 02/03/2026 12:30:00 PM
- Anavex Joins ACCESS-AD, a Major Initiative Funded by the European Commission, Through the Clinical Evaluation of Blarcamesine as Part of a Precision Medicine Approach in Alzheimer’s Disease • GlobeNewswire Inc. • 01/13/2026 12:30:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/09/2026 10:26:26 PM
- Edelson Lechtzin LLP Announces an Investigation of Anavex Life Sciences Corp. (NASDAQ: AVXL) and Encourages Investors with Substantial Losses Contact the Firm • PR Newswire (US) • 01/09/2026 01:13:00 AM
- Anavex Life Sciences Appoints Senior Vice President Global Head of Neurology • GlobeNewswire Inc. • 01/08/2026 12:30:00 PM
- Anavex Life Sciences Receives FDA Feedback on Alzheimer’s Disease Program • GlobeNewswire Inc. • 01/06/2026 12:30:00 PM
- Anavex Life Sciences Submitted Request for EMA to Re-Examine Its Opinion • GlobeNewswire Inc. • 12/18/2025 12:30:00 PM
- Anavex Life Sciences Provides Update on Regulatory Review in the EU for Blarcamesine to Treat Early Alzheimer’s Disease • GlobeNewswire Inc. • 12/12/2025 09:05:00 PM
